Clareo Health | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
Newly diagnosed patients with advanced EOC, 18-75 years of age: including patients with preoperative assessment of stage III-IV EOC, who underwent initial tumour cytoreduction and 6-8 courses of postoperative chemotherapy with paclitaxel + carboplatin/docetaxel + carboplatin;
Eastern Cooperative Oncology Group (ECOG) physical strength status (PS) score of 0 or 1;
Cooperation in the treatment process by providing clinicopathological data and imaging data required for the study process;
Cooperate with follow-up visits and collection of node blood for clinical efficacy assessment, and agree to use the test data for subsequent research and product development.
The initial and follow-up treatment processes are in accordance with NCCN guidelines;
You may not be if
Neoadjuvant chemotherapy patients;
Splenectomy patients;
Patients with contraindications to radiotherapy;
Any other patients who, in the judgement of the investigator, may have poor compliance with the procedures and requirements of the study;
Unacceptable or unavailable means of assessing specified efficacy such as imaging;
Vaccination within 2 months; antibiotics for infection within 2 weeks; history of blood transfusion within 2 weeks;
Long-term use of recombinant human erythropoietin, recombinant human interleukin, Ricodin tablets and other drugs affecting the composition of blood cells;
Severe organ dysfunction;
Infectious diseases such as immunodeficiency syndrome, active tuberculosis, HIV infection, and other infectious diseases not suitable for participation;
Pre-cancerous diseases of the blood, such as myelodysplastic syndromes;
Have received immunosuppressive therapy within 2 weeks;
